NRx Pharmaceuticals (NRXP) Q2 2026 earnings summary

Executive summary

• Achieved major milestones in Q2 2026, including FDA review progress for preservative-free ketamine ANDA, NRX-100 NDA advancement, and expansion of HOPE Therapeutics clinics.

• Completed acquisition of GeNeuro assets, adding clinical-stage monoclonal antibodies for ALS, schizophrenia, MS, and type 1 diabetes, with strong NIH and governmental partnerships.

• Selected as prime contractor for SPARC-TMS trial with anticipated non-dilutive funding exceeding $11.5 million, expanding NRX-101's market to over 15 million Americans.

• Expanded clinical footprint with HOPE clinics and new subsidiaries focused on military/first responder and neuroimmune therapeutics.

• Advanced toward commercial revenue and strengthened the balance sheet with new institutional investors and public offerings.

Financial highlights

• Net loss for the six months ended June 30, 2026, was $18 million, improved from $23.1 million in the same period of 2025.

• Net operating loss increased to $11.3 million from $7.6 million year-over-year, driven by higher R&D and SG&A costs for anticipated ketamine launch.

• Cash and cash equivalents rose to $26.7 million as of June 30, 2026, up from $7.8 million at year-end 2025, due to public offerings totaling over $22 million.

• Revenue of $2.2 million for H1 2026, all from Dura clinical services post-acquisition.

• Operating cash outflow of $13.2 million for H1 2026; financing activities provided $33 million, mainly from equity offerings.

Outlook and guidance

• Preservative-free ketamine ANDA approval targeted for 2026, with 5 million units of launch stock ordered and commercial-scale manufacturing initiated.

• NRX-100 NDA aiming for 2027 approval, leveraging real-world evidence as guided by recent federal directives.

• First-in-human trial for ALS drug GNK-301 targeted for July 2027, with substantial federal funding anticipated.

• Management expects current cash, pending launches, and clinic growth to support operations for at least a year, but may pursue additional financing for ongoing operations.

• Revenue expected to increase as Dura is fully integrated and clinical capacity expands.